Indication
Treatment of acute lymphoblastic leukaemia
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Loading your page…
Loading your page…
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marketing Authorisation Holder: ERYTECH Pharma S.A.
EMA Authorisation: 27/06/2018
INN: asparaginase
AI Drug & Interaction Analysis
Free account required
Ask Osler about Graspa: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.